The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK
Crossref DOI link: https://doi.org/10.1007/s12325-016-0367-9
Published Online: 2016-07-25
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ghosh, Wrik
Wickstead, Rose
Claxton, Lindsay
Kusel, Jeanette
Taylor, Matthew
Fleetwood, Kelly
Pulikottil-Jacob, Ruth
Funding for this research was provided by:
Novartis Pharmaceuticals UK Limited
License valid from 2016-07-25